This study is currently not recruiting participants.

Clinical Disease Manifestations associated with Anti-TNF Non-response in Juvenile Spondyloarthropathy

Investigating Treatment Response in Juvenile Spondyloarthropathy

Not Recruiting
100 years or below
All
1 Location

Brief description of study.

The purpose of this study is to define treatment response and non-response for JSpA patients and to identify the clinical characteristics associated with TNFi therapy failure.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Juvenile Spondyloarthropathy
  • Age: 100 years or below
  • Gender: All

Inclusion Criteria

This study will include juvenile spondyloarthropathy(JSpA) patients who have not responded to TNFi therapy, specifically etanercept, adalimumab, infliximab, golimumab or certolizumab pegol. JSpA diagnosis will be defined as 16 years or younger at time of diagnosis and include the following JSpA subtypes: enthesitis related arthritis, psoriatic arthritis, undifferentiated spondyloarthritis, juvenile ankylosing spondylitis and reactive arthritis.

Exclusion Criteria

Patients who do not having a diagnosis of juvenile spondyloarthropathy(JSpA) will be excluded.

This study investigates how patients with juvenile spondyloarthropathy (JSpA) respond to treatment. Juvenile spondyloarthropathy is a type of arthritis that affects children and can cause pain and swelling in the joints. The study aims to understand why some treatments may not work well for certain patients and what clinical features are linked to the failure of TNFi therapy, which is a type of treatment for JSpA.

Participants in this study will undergo assessments to determine their response to treatment. This will help identify specific characteristics of JSpA patients who do not respond to TNFi therapy, which includes medications like etanercept, adalimumab, infliximab, golimumab, or certolizumab pegol. The study will involve examining different subtypes of JSpA, such as enthesitis-related arthritis and psoriatic arthritis.

  • Who can participate: Children aged 16 or younger diagnosed with juvenile spondyloarthropathy (JSpA) who have not responded to TNFi therapy are eligible to participate. The study includes various subtypes of JSpA, such as enthesitis-related arthritis and psoriatic arthritis.
  • Study details: Participants will be assessed to determine their response to TNFi therapy. This involves examining clinical characteristics to identify why some patients do not respond to treatment.
Updated on 19 Feb 2024. Study ID: 1812741336

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team